We are live on ! Find out more
FENC icon

Fennec Pharmaceuticals

43 hedge funds and large institutions have $120M invested in Fennec Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,227% more call options, than puts

Call options by funds: $3.09M | Put options by funds: $233K

260% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 5

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

43% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 7

39% more funds holding

Funds holding: 3143 (+12)

30% more capital invested

Capital invested by funds: $92.1M → $120M (+$27.5M)

3.81% more ownership

Funds ownership: 43.6%47.42% (+3.8%)

Holders
43
Holders Change
+12
Holders Change %
+38.71%
% of All Funds
0.69%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
18
Increased
10
Reduced
7
Closed
5
Calls
$3.09M
Puts
$233K
Net Calls
+$2.86M
Net Calls Change
+$5.09M
Name Holding Trade Value Shares
Change
Change in
Stake
SCA
1
Southpoint Capital Advisors
New York
$39.1M
SGL
2
Sonic GP LLC
Hawaii
$23.1M +$21.3M +2,407,357 New
SCM
3
Solas Capital Management
Connecticut
$12M +$1.07M +121,221 +11%
ACA
4
Avoro Capital Advisors
New York
$11.5M
DCM
5
DG Capital Management
New York
$9.81M +$149K +16,851 +2%
HFA
6
Harbert Fund Advisors
Alabama
$3.04M +$1.13M +127,199 +67%
6CM
7
683 Capital Management
New York
$2.88M -$751K -84,824 -22%
OM
8
Opaleye Management
Massachusetts
$2.61M +$2.41M +272,200 New
TA
9
Tamarack Advisers
California
$2.04M +$336K +38,000 +22%
EI
10
EAM Investors
California
$1.69M -$3.26K -368 -0.2%
GJL
11
Gendell Jeffrey L
$1.47M +$1.35M +153,070 New
Millennium Management
12
Millennium Management
New York
$1.22M -$1.08M -122,048 -49%
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$1.03M +$952K +107,613 New
CIBC World Market
14
CIBC World Market
Ontario, Canada
$954K +$879K +99,363 New
1CM
15
1492 Capital Management
Wisconsin
$911K +$839K +94,870 New
Two Sigma Investments
16
Two Sigma Investments
New York
$842K +$776K +87,671 New
ACA
17
Apis Capital Advisors
New York
$557K +$513K +58,000 New
Two Sigma Advisers
18
Two Sigma Advisers
New York
$528K +$487K +55,000 New
TS
19
Tamar Securities
California
$513K
BlackRock
20
BlackRock
New York
$485K +$10.4K +1,177 +2%
Morgan Stanley
21
Morgan Stanley
New York
$436K +$82.4K +9,314 +26%
HFM
22
Hartford Financial Management
Connecticut
$383K
BCM
23
Bridgeway Capital Management
Texas
$328K +$303K +34,200 New
Citadel Advisors
24
Citadel Advisors
Florida
$269K +$110K +12,378 +79%
Jane Street
25
Jane Street
New York
$248K +$101K +11,359 +78%

FENC Hedge Fund Activity: Q4 2022 in Review

43 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q4 2022, worth a combined $120M — up 30% from $92.1M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new FENC positions and 5 closed out — a net gain of 13 holders — while 10 added to existing stakes and 7 trimmed.

The largest buyer was Opaleye Management, opening a new position worth an estimated $2.41M. The largest seller was Millennium Management, cutting an estimated $1.08M.

  • 43 institutional investors held Fennec Pharmaceuticals (FENC) as of Q4 2022, up from 31 in Q3 2022.
  • Funds reported $120M of Fennec Pharmaceuticals stock for Q4 2022, up 30% quarter-over-quarter.
  • 18 funds opened new Fennec Pharmaceuticals positions in Q4 2022 and 5 closed out, a net change of +13 holders.
  • The largest Fennec Pharmaceuticals buyer in Q4 2022 was Opaleye Management, an estimated $2.41M added.
  • The largest Fennec Pharmaceuticals seller in Q4 2022 was Millennium Management, an estimated $1.08M sold.

Based on aggregated 13F filings for Q4 2022.